This section contains two parts primarily providing information for your doctor. They are as follows:
Carnitine-Doxorubicin Clinical Study for the Treatment of Stages III-IV Ovarian Cancer
There is a summary written by Dr. DeFelice describing how the carnitine-doxorubicin story began as well as a description of selected publications which support the potential clinical effectiveness and safety of carnitine. It also contains a description of the clinical protocal.
The Carnitine-Doxorubicin Promise for the Treatment of Ovarian Cancer
This section contains the results of selected published scientific studies either as complete publications, abstracts, or summaries either directly or indirectly, supporting the potential of carnitine-doxorubicin for the treatment of cancer in general.
The clinical design of the study is included as well as the FDA approved package inserts of both oral and intravenous carnitine.
Items linked below will download as .pdf files which can be viewed and printed in Mac Preview or Acrobat Reader.
1. A review of carnitines clinical cardiovascular profile by Dr. Carl J. Pepine entitled, The Therapeutic Potential of Carnitine in Cardiovascular Disorders. Though it was published in 1991, and more positive clinical studies have followed since then, this review covers carnitines broad clinical potential including doxorubicin cardiotoxicity.
2. Chinese hamster ovarian culture cell abstract.
3. Vanderbilt Human ovarian cancer culture study.
4. Fatty acid proposed mechanism of action the human colon cancer cells.
5. Mitochondrion and death ligand proposed mechanism of action mouse hepatic cancer cells.
6. Chronic preclinical studies demonstrating carnitines ability to block doxorubicins toxicity.
READ ITEM 1> READ ITEM 2> READ ITEM 3>
7. Clinical study on patients with non-Hodgkins lymphoma demonstrating that carnitine blocks doxorubicins cardiotoxicity as well as corrects doxorubicin-induced mitochondrial toxicity.
10. Low carnitine levels in adult and pediatric cancer patients.
11. Examples of carnitines broad anti toxic activity are AZT, methotrexate, carboplatinum, formaldehyde and diphtheria toxin.
READ ITEM 1> READ ITEM 2> READ ITEM 3> READ ITEM 4> READ ITEM 5>
READ ITEM 6>
12. Protocol of the clinical study.
13. Carnitine package inserts, Sigma tau-Carnitor, for the intravenous and oral forms.
Warning: All three Carnitines are available as dietary supplements in commercial outlets and should only be taken for a serious medical condition under a physician's supervision.
Next page: In the News